Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Top Cited Papers
- 23 September 2016
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 27 (suppl_5) , v38-v49
Abstract
Almost one million (951 600) new cases of gastric cancer were diagnosed globally in 2012, resulting in ∼723 100 deaths [1]. Of these ∼140 000 cases and ∼107 000 deaths occurred in Europe [2]. Gastric cancer displays significant global variation in incidence; the highest rates are seen in Eastern Asia, Eastern Europe and South America, with lower rates in North America and Western Europe. A gradual decline in the incidence of gastric cancer has been observed in Western Europe and North America over the past 60 years and more recent declines in high-prevalence countries have also become apparent. This is epidemiologically distinct from the relative increase in tumours of the gastroesophageal junction, which are discussed in a separate guideline document.Keywords
This publication has 91 references indexed in Scilit:
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialThe Lancet Oncology, 2013
- Differences in outcomes of oesophageal and gastric cancer surgery across EuropeBritish Journal of Surgery, 2012
- Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical TrialAnnals of Surgical Oncology, 2011
- Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954Journal of Clinical Oncology, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Nurse-led follow-up of patients after oesophageal or gastric cardia cancer surgery: a randomised trialBritish Journal of Cancer, 2008
- A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancerBritish Journal of Cancer, 2008
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerNew England Journal of Medicine, 2008
- Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study GroupJournal of Clinical Oncology, 2006
- Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trialsEuropean Journal of Cancer, 2006